Company intelligence / Profile preview

TCI

Ownership: Private
Employees: ~1120
Development stage: Commercial

Overview

TCI is a global leader in the research, development, and manufacturing of functional foods and skincare products as a CDMO+. The company leverages advanced bioscience design methodologies to deliver clinically backed supplements and cosmetics at commercial scale. It has demonstrated strong financial performance with NT$7.24 billion revenue in 2024 and continues to expand globally with a focus on sustainability.

Therapeutic areas: OtherDermatology
Modalities: Small molecule (nutritional ingredients)ProbioticsPeptides (e.g., collagen-based products)Recombinant protein (e.g., hyaluronic acid biomaterials)
Industry: Contract Manufacturing Organization

Partnerships

Notable partnerships with global supplement brands/private label clientsStrategic collaborations in R&D/manufacturing but specific names not disclosed publicly

Beyond the preview

Go deeper on TCI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCI.

Explore the full profile